Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Li, Congfen ^a   Takahashi, Chikara ^a   Zhang, Liangxuan ^a   Huseni, Mahrukh ^a   Stankovich, Basha ^b   Mashhedi, Haider ^a   Lee, Joanna ^a   French, Dorothy ^a   Anderson, Jeff Eastham ^a   Kim, Doris ^a   Howell, Kathy ^a   Brauer, Matthew J ^a   Kowanetz, Marcin ^a   Yan, Yibing ^a   Humke, Eric ^a   Ebens, Allen ^a   Hampton, Garret ^a   Lackner, Mark R ^a   Hegde, Priti ^a   Jia, Shidong ^a  

^a GENENTECH INC   (United States)

^b AllCells LLC   (United States)

Author keywords

Biomarker; Clinical trial; Flow cytometry; Immunohistochemistry; Meso Scale Discovery; Multiple myeloma; Pharmacodynamics; Phosphatidylinositol 3 kinase

Indexed keywords

BIOLOGICAL MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; S6 KINASE;

ARTICLE; CELL POPULATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTERMETHOD COMPARISON; MESO SCALE DISCOVERY ASSAY; MULTIPLE MYELOMA; PHARMACODYNAMICS; PROCESS DEVELOPMENT; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; SAMPLING; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BONE MARROW; BONE MARROW CELLS; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INDAZOLES; MULTIPLE MYELOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84875148984     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-76     Document Type: Article

References (16)

1. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7(8):585-598.
2. Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010, 116(9):1460-1468. 10.1182/blood-2009-06-222943, 2938837, 20505158.
3. Steinbrunn T, Stuhmer T, Sayehli C, Chatterjee M, Einsele H, Bargou RC. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. Br J Haematol 2012, 159(4):430-440. 10.1111/bjh.12039, 22985491.
4. Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, Anderson KC, Ghobrial IM. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res 2007, 13(13):3771-3775. 10.1158/1078-0432.CCR-06-2921, 17606706.
5. Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs 2012, 23(1):131-138. 10.1097/CAD.0b013e32834c8683, 21959532.
6. Munugalavadla V, Mariathasan S, Slaga D, Du C, Berry L, Del Rosario G, Yan Y, Boe M, Sun L, Friedman LS. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Oncogene 2013, [Epub ahead of print].
7. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer?. Curr Opin Cell Biol 2009, 21(2):199-208. 10.1016/j.ceb.2008.12.007, 3142565, 19200708.
8. Lackner MR. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. Expert Rev Mol Diagn 2010, 10(1):75-87. 10.1586/erm.09.78, 20014924.
9. Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, Signoretti S, Loda M, Zhao JJ, Roberts TM. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 2013, 3(1):44-51. 10.1158/2159-8290.CD-12-0262, 23258246.
10. Fuhler GM, Diks SH, Peppelenbosch MP, Kerr WG. Widespread deregulation of phosphorylation-based signaling pathways in multiple myeloma cells: opportunities for therapeutic intervention. Mol Med 2011, 17(7-8):790-798. 3146594, 21541441.
11. Liu Y, Hegde P, Zhang F, Hampton G, Jia S. Prostate cancer - a biomarker perspective. Front Endocrinol (Lausanne) 2012, 3:72.
12. Olmos D, Baird RD, Yap TA, Massard C, Pope L, Sandhu SK, Attard G, Dukes J, Papadatos-Pastos D, Grainger P. Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res 2011, 17(15):5188-5196. 10.1158/1078-0432.CCR-10-3019, 21531820.
13. Brey EM, Lalani Z, Johnston C, Wong M, McIntire LV, Duke PJ, Patrick CW. Automated selection of DAB-labeled tissue for immunohistochemical quantification. J Histochem Cytochem 2003, 51(5):575-584. 10.1177/002215540305100503, 12704205.
14. Krutzik PO, Irish JM, Nolan GP, Perez OD. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 2004, 110(3):206-221. 10.1016/j.clim.2003.11.009, 15047199.
15. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13(7):843-850. 10.1038/nm1592, 17558415.
16. Krutzik PO, Trejo A, Schulz KR, Nolan GP. Phospho flow cytometry methods for the analysis of kinase signaling in cell lines and primary human blood samples. Methods Mol Biol 2011, 699:179-202. 10.1007/978-1-61737-950-5_9, 21116984.